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OBJECTIVE: We examined the demographic and clinical profiles of Parkinson’s disease in Shanghai, China, to
assist in disease management and provide comparative data on Parkinson’s disease prevalence, phenotype, and
progression among different regions and ethnic groups.
METHODS: A door-to-door survey and follow-up clinical examinations identified 180 community-dwelling Han-
Chinese Parkinson’s disease patients (104 males, 76 females).
RESULTS: The average age at onset was 65.16¡9.60 years. The most common initial symptom was tremor (112
patients, 62.22%), followed by rigidity (38, 21.11%), bradykinesia (28, 15.56%) and tremor plus rigidity (2,
1.11%). Tremor as the initial symptom usually began in a single limb (83.04% of patients). The average duration
from onset to mild Parkinson’s disease (Hoehn-Yahr phase 1–2) was 52.74¡45.64 months. Progression from
mild to moderate/severe Parkinson’s disease (phase$3) was significantly slower (87.07¡58.72 months;
p,0.001), except for patients presenting initially with bradykinesia (53.83¡24.49 months). Most patients
(149/180, 82.78%) took levodopa with or without other drugs. The Hamilton Anxiety Scale revealed symptoms
of clinical anxiety in 35 patients, and the Hamilton Depression Scale revealed depressive symptoms in 88
patients. The depressed or anxious subgroup (123 patients) demonstrated a significantly younger age at onset
(55.54¡7.68 years) compared with the overall mean (p,0.05).
CONCLUSION: Unilateral limb tremor was the most common initial symptom, and motor function deteriorated
slowly over <429 years. Earlier-onset patients experience greater psychiatric dysfunction.
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& INTRODUCTION
Parkinson’s disease (PD) results from the progressive
degeneration of dopaminergic neurons in the substantia
nigra (1). Although several gene mutations causing familial
PD have been identified (2-4), the etiology of the more
common idiopathic form remains unclear.
The first symptom of idiopathic PD may be a change in
the sense of smell (4), but motor dysfunction (manifested as
resting tremor, rigidity, or bradykinesia) is the first serious
deficit, most often afflicting a single distal limb (1). Reduced
dopaminergic activity in the substantia nigra in turn
enhances cholinergic signaling (5). Therefore, pharmaceutical
therapies aim to restore the balance between dopaminergic
and cholinergic neurotransmission and include anti-
cholinergics, dopamine replacement therapies, dopamine
receptor agonists and inhibitors of dopamine degradation (5).
Unfortunately, these therapies do not arrest or markedly
slow the degeneration of dopaminergic neurons (6,7).
However, medication, surgery and rehabilitation can provide
motor symptom relief and improve patient quality of life (8-
13). These treatments may be most effective when initiated in
the earliest stages of the disease (4), but there is no consensus
on this issue.
The prevalence of PD continues to increase in mainland
China as the population ages. A recent epidemiological
study (14) reported an incidence of 1.07% in Chinese citizens
over 55 years old, 1.7% in those over 65 and 2.5% in
individuals over 75, an age dependence similar to that
reported in Europe and the United States (1). There are
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currently approximately six million Chinese PD patients
and the annual rate of new case development is estimated at
100,000 (14). However, most patients and their families have
limited knowledge of the disease and are unaware of its
initial symptoms, delaying diagnosis and treatment initia-
tion. In addition, regional prevalence varies widely (15).
Here, we utilized integrated medical resources and a
complete medical service platform to conduct a door-to-
door survey in the Gumei community of Shanghai’s
Minhang district. The survey and follow-up medical
examinations ultimately identified 180 PD patients. The
data accrued from these patients were retrospectively
reviewed to identify the earliest symptoms and disease
progression. These results may facilitate earlier diagnosis
and improve clinical management in this community.
& MATERIALS AND METHODS
Population
This was a single-center study based in a single commu-
nity. The sampling population comprised Han residents
living in the Gumei community of Minhang district,
Shanghai, who had medical records archived in the local
health service center. Gumei is located in southwest
Shanghai between the suburbs and the city. The residents
originate from various regions of the Yangtze River delta
region of China and thus constitute a convenient sample
population for studying the characteristics of PD in this
region. The study was approved by the local ethics
committee and each enrolled PD patient provided written
informed consent.
The standard diagnostic criteria for PD (16) include a slow
disease onset with at least two of the following manifesta-
tions: (1) resting tremor or bradykinesia responsive to
levodopa, (2) rigidity, or (3) abnormal gait/posture.
Physical examination, auxiliary tests, questionnaire
assessment and documentation of disease history were all
conducted by physicians with neurology training. We
referred to the standard PD diagnostic criteria (16) to
develop the questionnaire. None of the subjects had a
history of contact with the specific dopaminergic neurotoxin
MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) and
patients with Parkinson’s syndrome or Parkinson’s overlap
syndrome were excluded. None of the enrolled PD patients
had cerebellar signs, pyramidal signs, or orthostatic
hypotension. The demographic characteristics recorded
were age, gender, marital status and occupation. Medical
history included the presence of hypertension, diabetes,
hyperlipidemia, coronary heart disease, blood hyperviscos-
ity syndrome, smoking and drinking habits, cerebrovascular
diseases (including hemorrhagic and ischemic lesions), drug
poisoning and head trauma. Clinical information on PD
included age at onset, major symptoms and signs, and
detailed disease course.
& METHODS
Community medical practitioners were specifically trained
to identify PD symptoms. Individuals with at least one PD
symptom (resting tremor, bradykinesia, rigidity, or abnormal
gait/posture) were registered in the first phase. These
potential PD patients were then recruited for physical
examinations and detailed assessment of medical history at
the Gumei Health Center by neurologists who confirmed PD
and determined the clinical stage. The PD stage was
determined according to the revised Hoehn-Yahr scale,
which considers multiple PD parameters, including age at
onset, initial symptoms, progression and effects of medica-
tion (16). The PD stage was further assessed using the unified
PD Rating Scale (UPDRS) (17), while associated depression
and anxiety were assessed by the Hamilton Depression Scale
(HAMD) (18) and the Hamilton Anxiety Scale (HAMA) (19).
We classified 180 PD patients into three groups according
to their initial symptom: tremor, bradykinesia, or rigidity.
Statistical analysis
Data are expressed as the mean ¡ standard error of the
mean (SEM). SAS11.0 software (SAS Institute Inc., Cary,
NC) was used for all statistical analyses. Unpaired t tests
were performed to compare continuous variables between
two groups. Chi-square (x2) tests were used to compare
categorical results among multiple groups, and the means of
multiple groups were compared using Kruskal-Wallis one-
way analysis of variance (ANOVA) followed by Dunn’s
post hoc test. P,0.05 was considered statistically significant.
& RESULTS
General survey information
We interviewed 36,981 residents of Gumei during a door-
to-door survey conducted between June 2008 and December
2011. We identified 180 PD patients (104 males, 76 females)
ranging from 35 to 94 years of age (mean age, 65.16¡9.60
years). Among the participants, 126 were local residents
(with medical insurance cards issued by Shanghai) and 54
were non-locals (including migrant workers and elderly
individuals living with their children who did not have
Shanghai citizen medical insurance cards but who had
legally lived in Shanghai for at least 2 years). Only one
female patient had a family history of PD (her mother).
Parkinson’s disease prevalence by age
The patient population was divided into five groups by
age range (years): 15249, 50259, 60269, 70279, and $80.
The prevalence of PD was positively correlated with age in
patients 50279 years of age and was highest in the 70279
year group (62/4143, 1.496%) (Table 1).
Prevalence of depression and anxiety by age
The youngest two groups exhibited the highest scores on
the HAMA and HAMD scales, indicating higher rates of
anxiety and depression in younger PD patients, whereas the
scores were negatively correlated with age in patients older
than 60 years (Table 1).
Initial symptoms
Tremor was the most common initial symptom (112 of 180
patients, 62.22%), followed by rigidity (38/180, 21.11%) and
bradykinesia (28/180, 15.56%). Two male patients had both
tremor and rigidity at disease onset (2/180, 1.11%). The sex
ratio (male:female) did not differ significantly among
groups defined by initial symptom (tremor: 1.18:1.00,
rigidity: 1.11:1.00, bradykinesia: 1.33:1.00; p= 0.796).
Age at onset
The average age at onset was 65.16¡9.60 years of age,
with the majority of patients exhibiting initial symptoms
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between 60 and 79 years of age (131/178, 73.60%). The age at
onset in the tremor group was older than that in either of the
other two groups and significantly older than that in the
rigidity group (p= 0.014). Tremor was the most common
initial symptom in every age group (Table 2) but was
particularly frequent in patients with older age at onset
($60 years).
Initially affected body part
The body part or parts first affected are presented in
Table 3. The two patients who experienced two initial
symptoms (tremor and rigidity) were excluded from the
analysis. In the remaining 178 patients, the PD initial
symptom usually afflicted only a single limb (131/178,
73.60%) and was most frequently tremor (93/131, 70.99%).
Thus, the vast majority of patients first presenting with
tremor (112) exhibited tremor in only one limb (93/112,
83.04%) and this unilateral tremor started most often in a
right limb (68/93, 73.12%). Similarly, rigidity usually first
presented in a single limb (28/38, 73.68%). In contrast,
bilateral limb onset was relatively more common when
bradykinesia was the first symptom (39.28% vs. 10.71%
bilateral tremor and 10.53% bilateral rigidity).
Disease progression
There were 101 patients classified as mild and 77
classified as moderate/severe according to the revised
Hoehn-Yahr scale (12,17). The average delay from the initial
symptom to mild PD (stages 122) was 52.74¡45.64 months.
Progression from mild to moderate/severe PD (stages 325)
required 87.07¡58.72 months, significantly longer than the
delay from the initial symptom to mild PD (p,0.001).
Disease severity differed significantly among groups classi-
fied according to the initial symptom (p=0.025). The
duration from the initial symptom to mild PD was similar
among groups (p.0.05), but the duration from mild to
moderate/severe was significantly shorter in the bradyki-
nesia group compared with the tremor and rigidity groups
(p= 0.012 and 0.006, respectively) (Table 4). We did not
observe a significant difference between the tremor and
rigidity groups (p=0.448), suggesting that PD with first-
onset bradykinesia is a more rapidly progressing variant.
Pharmaceutical and non-pharmaceutical
treatments
The majority of patients were treated with either
levodopa (83/180, 46.11%) or a combination of levodopa
and at least one additional drug (66/180, 36.67%), including
amantadine (5/180, 2.78%), artane (trihexyphenidyl hydro-
chloride) (6/180, 3.33%), a monoamine oxidase B inhibitor
(MAO-B) or dopamine agonists (6/180, 3.33%), or coenzyme
Q10 (2/180, 1.11%). Twelve patients (6.67%) did not take
any type of medication.
Deep brain stimulation (DBS) is a relatively new therapy
in China, and only 4/180 patients (2.22%) in this population
had undergone DBS.
& DISCUSSION
The initial manifestations of PD differ among patients
both with regard to severity and the afflicted region (20).
Many patients do not recognize these early symptoms and
the rate of early diagnosis is therefore low (21), greatly
reducing the potential efficacy of current therapies for
improving quality of life. A more detailed description of the
earliest symptoms, combined with greater awareness
among at-risk populations, may facilitate earlier PD
diagnosis and improve QOL.
Aging
Epidemiological studies have shown that PD prevalence
and incidence correlate strongly with age; therefore, age is
one of the strongest risk factors for PD (1). The case-
controlled design is most commonly used in PD studies due
to the limited number of cases within a given sampling
population and the variability in clinical profile (22). In the
Table 1 - Parkinson’s disease prevalence and psychiatric status by age range (years).
Group Number, n (%)
Total 15249 50259 60269 70279 $80
Parkinson’s disease patients 180 5 31 69 64 11
Registered population 36,981 17,210 6028 5512 4143 4088
Parkinson’s disease prevalence 0.480% 0.041% 0.513% 1.252% 1.496% 0.268%
HAMA 16.4¡3.1* 14.4¡2.8* 10.4¡3.3 11.2¡2.9 8.7¡3.4
HAMD 7.4¡3.4* 7.1¡3.3* 5.2¡3.2 4.7¡3.4 4.5¡3.6
HAMA: Hamilton anxiety scale (18). Mild: 0217, Mild/Moderate: 18225, Moderate/Severe: 26230, Very Severe: .30.
HAMD: Hamilton depression scale (19). Normal: 0–7, Clinical: .20.
PD: Parkinson’s disease.
*p,0.001 vs. 60269 years.
Table 2 - Initial Parkinson’s disease symptoms and age at onset (years).
Initial
Symptom Total (%) M/F 15249 50259 60269 70279 $80 Avg Range
Tremor 112 (62.92%) 66/46 2 (40.00%) 19 (61.29%) 45 (65.22%) 42 (65.61%) 4 (36.36%) 61.19¡9.74* 34294
Rigidity 38 (21.34%) 20/18 1 (20.00%) 7 (22.58%) 13 (18.84%) 12 (18.78%) 5 (45.46%) 56.32¡9.62 31286
Bradykinesia 28 (15.73%) 16/12 2 (40.00%) 5 (16.13%) 11 (15.94%) 10 (15.61%) 2 (18.18%) 59.39¡7.35 45287
Note: M/F: male/female; Avg: average age at onset of symptom; Range: range of ages for specific symptom onset, *p,0.05 tremor group vs. rigidity group.
Two patients with at least two initial symptoms were excluded from the table.
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present study, we interviewed 36,981 people using a door-
to-door survey and identified only 180 confirmed PD
patients. Similarly, a study by Harvard University and the
University of Pennsylvania (23) identified only 160 PD
patients out of 50,000 interviewees. The higher PD pre-
valence observed in our study may reflect differences in
population demographics and inclusion/exclusion criteria,
such as updated PD diagnostic criteria (16) and the
exclusion of potential patients younger than 14 years, the
minimum age for registration at local health centers.
Nonetheless, both surveys indicate that very large sample
sizes are required to gather sufficient information on PD
patients to establish specific clinical subgroups.
Psychiatric symptoms
Psychiatric symptoms such as anxiety and depression are
more common in PD patients than in the general population
(1), although the rate varies across sample populations. In
the current study, 16 patients with anxiety symptoms were
taking appropriate anti-anxiety medication and receiving
psychiatric therapy, but 29 patients with anxiety symptoms
were not receiving any treatment. Similarly, according to the
HAMD, 88 patients exhibited signs of depression, but only
17 were treated. This is consistent with other PD patient
populations (24) in which the psychiatric symptoms are
often regarded as secondary to the motor symptoms. The
average age at PD onset in the 45 patients with anxiety and
88 patients with depression was 55.54¡7.68 years, signifi-
cantly younger than the overall mean PD age at onset
(65.16¡9.60 years). Whether this association reflects greater
anxiety due to early onset (a situational factor), a common
neurocellular etiology (25), or whether these psychiatric
disorders can in fact exacerbate core PD symptoms or
accelerate progression is a matter of current debate. It is
clear that depression and anxiety interfere with memory
and executive function, suggesting that they may exacerbate
the cognitive symptoms of PD (26,27).
Correlation between initial symptom and age of
onset
The most common initial symptom in our study was
tremor (62.22% overall), which was within the range of
55%274% reported in previous studies (28). It should be
noted, however, that the reported incidence of tremor as the
first symptom may be inflated, as tremor is more noticeable
than mild rigidity and bradykinesia. Uitti et al. (29) reported
tremor as the initial symptom in only 47% of a large PD
population (585/1244). This same study also reported a
higher rate of bradykinesia as the initial symptom (29%,
361/1244) when compared with the 15.56% (28/180) in our
study. The average age at onset was older in patients with
tremor as the principal onset symptom compared with
patients reporting rigidity or bradykinesia as the onset
symptom (the combined group), suggesting that ‘‘tremor-
first’’ PD is a milder clinical variant. PD occurring after age
50 is considered late onset (30,31). By this definition, 62.86%
(110/175) of all late-onset cases in our study presented first
with tremor, indicating that tremor is a more common initial
symptom in late-onset patients, in agreement with a report
by Helmich et al. (32). Bostantjopoulou et al. (33) also found
that tremor was the most common onset symptom in
patients over 68 years old, whereas rigidity and bradykine-
sia were relatively more common onset symptoms in
middle-aged (early onset) patients. We found that tremorT
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patients were older than rigidity patients (p,0.05), but age
at onset was not different between tremor and bradykinesia
patients or rigidity and bradykinesia patients (both p.0.05).
Larger sample sizes are required to assess whether rigidity-
first PD and bradykinesia-first PD follow distinct courses.
It was reported that the prevalence of tremor as the onset
symptom was negatively correlated with age, whereas
rigidity as the first symptom was positively correlated with
age (34). However, tremor was the most common onset
symptom in every age group in our study and all symptoms
had a similar age at onset (between 50 and 69 years old).
Thus, our results suggest that tremor-first PD is a less-
aggressive variant, but larger-scale studies including greater
numbers of rigidity-first and bradykinesia-first patients are
needed to clarify this issue.
Initially affected body part
The majority of patients exhibited their first noticeable
symptom in a unilateral limb and this proportion was
highest in tremor-first patients. A previous study also
reported unilateral limb onset in a majority of PD patients,
with the highest prevalence in tremor-first patients (34). The
right limb was the first affected body part in the majority of
tremor-first and rigidity-first PD patients, whereas another
study reported that tremor more often started in a left limb
and bradykinesia generally afflicted both limbs at onset (1).
These differences are of significant interest because they
reflect differences in progression at the neurocellular level
and may therefore provide insight into the etiology of
sporadic PD. The sample population came from different
regions of the Yangtze River delta, but all were of Han
ethnicity. Whether these discrepancies with previous
studies reflect the influence of region or ethnicity warrants
further study.
Disease progression
We graded PD as mild or moderate/severe according to
the revised Hoehn-Yahr system (16). The duration from first
symptom onset to mild PD (52.74¡45.64 months) was
significantly shorter than the time to progress from mild to
moderate/severe PD (87.07¡58.72 months). The disease
was the most severe and progression the fastest in patients
with bradykinesia as the onset symptom. Alternatively,
there was no difference between the rigidity and tremor
groups in terms of PD progression, but patients who
reported tremor as the first symptom were typically older
and experienced slower disease development. It has been
postulated that the rate of dopaminergic neuron degenera-
tion is slower in patients presenting first with tremor
compared with other PD subtypes (35). However, Jankovic
and Kapadia (36) found that later-onset patients, which may
include a greater proportion of tremor-first patients, had
more rapidly progressing disease according to the UPDRS
and ADL scoring systems.
We conducted a survey of PD prevalence, phenotype and
progression in an ethnically homogenous population of
community-dwelling Han Chinese to provide additional
comparative data for more effective clinical management.
Whereas this study surveyed almost 37,000 residents, only
180 confirmed PD cases were identified. Thus, our data
concerning unusual phenotypes are limited and it appears
that a very large-scale multicenter study will be necessary to
accurately assess the initial characteristics and progression
of patients presenting first with bilateral bradykinesia or
bradykinesia in all limbs. Furthermore, non-drug therapies
are still rare in China, as are certain specific drug
combinations.
Our retrospective analysis of 180 PD patients in the
Gumei community of Shanghai revealed that tremor was
the most common onset symptom in this community. Most
tremor patients had late-onset PD with a right limb affected
first and this disease variant progressed relatively slowly
compared with PD with bradykinesia as the first symptom.
Symptoms of anxiety and depression were associated with
lower age of onset, implying that psychiatric treatment may
be an integral aspect of therapy for early-onset PD.
Comparative Epidemiology
A recent meta-analysis of 13 epidemiological studies from
China reported a pooled peak prevalence of 1.663% (in
patients $80 years old) and an overall incidence of 797 per
100,000 person-years with a male predominance (37).
Moreover, the prevalence was said to be lower in China
than in most developed countries but the incidence higher
than in some developing countries. From a survey of urban
and rural communities around the large cities of Beijing,
Xian and Shanghai, Zhang et al. (14) reported a PD
prevalence of 1.7% for those older than 65. Both prevalence
estimates are slightly higher than the peak value of 1.496%
(in patients 70279 years old) reported in the current study.
However, all these estimates are consistent with the lower
PD prevalence in Asian countries compared with North
America and Europe (38). Moreover, non-motor symptom
expression may also differ between Asian and Western
countries (39), underscoring potential differences in PD
presentation among ethnic groups. Differences in PD
prevalence between countries or ethnic groups may be
influenced by differences in life expectancy or the avail-
ability of diagnostic facilities, but incidence estimates tend
to confirm a lower incidence of PD in Asians and Africans
(including African Americans) compared with Europeans
(37,40). These differences have been attributed to genetic
variations, such as differences in single nucleotide poly-
morphism (SNP) patterns in PD-associated genes, including
Table 4 - Parkinson’s disease progression among patients with different onset symptoms.
Severity Number Tremor Rigidity Bradykinesia
Average duration (months)
Mild stage 101 53.18¡47.91 (n = 64) 53.57¡40.63 (n= 21) 49.38¡41.87 (n= 16)
Moderate/severe stage 77 90.41¡62.17* (n =41) 105.24¡62.94* (n= 26) 52.14¡24.10 (n= 10)
Note: Mild PD: Hoehn-Yahr phase 1–2; Moderate/severe PD: Hoehn-Yahr $ phase 3.
*p,0.01 vs. Bradykinesia patients. Two patients with at least two initial symptoms were excluded from the table.
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LRRK2, across populations (41) and to lifestyle and
environmental differences. Lifestyle factors include smok-
ing (42), coffee consumption (43), medical compliance (44),
nutrition (45) and exercise (46), whereas well-studied
environmental factors include toxins such as pesticides
(47). Any of these factors may account for the differences
across studies of Han Chinese populations. However, many
of these associations between environmental factors and PD
have not been replicated consistently (48), suggesting
methodological flaws or more complex gene-environment
interactions.
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